Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Dae Hyun | - |
dc.contributor.author | Yoon, Jai Hoon | - |
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Lee, Oh Young | - |
dc.contributor.author | Yoon, Byung Chul | - |
dc.contributor.author | Lee, Hang Rak | - |
dc.contributor.author | Kim, Kyung Soo | - |
dc.contributor.author | Choi, Ho Soon | - |
dc.date.accessioned | 2021-08-02T09:52:59Z | - |
dc.date.available | 2021-08-02T09:52:59Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 2288-8128 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/10692 | - |
dc.description.abstract | Tyrosine kinase inhibitors are widely used as targeted treatments for various malignancies. Sorafenib is an orally active tyrosine kinase inhibitor that blocks the signaling pathways of several growth factors. Its use is approved for various malignancies such as unresectable hepatocellular carcinoma, renal cell carcinoma, and gastrointestinal stromal tumors. Several adverse effects have been reported in the literature; however, cardiotoxicity is rare. We present a case of recurrent coronary vasospasm caused by short-term administration (5 days) of sorafenib. Since it caused refractory ischemia after re-administration, we had no choice but to stop the treatment. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | The Korean Liver Cancer Association | - |
dc.title | Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Jai Hoon | - |
dc.contributor.affiliatedAuthor | Jun, Dae Won | - |
dc.contributor.affiliatedAuthor | Lee, Oh Young | - |
dc.contributor.affiliatedAuthor | Yoon, Byung Chul | - |
dc.contributor.affiliatedAuthor | Choi, Ho Soon | - |
dc.identifier.doi | 10.17998/jlc.20.1.67 | - |
dc.identifier.scopusid | 2-s2.0-85172221592 | - |
dc.identifier.bibliographicCitation | Journal of Liver Cancer, v.20, no.1, pp.67 - 71 | - |
dc.relation.isPartOf | Journal of Liver Cancer | - |
dc.citation.title | Journal of Liver Cancer | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 67 | - |
dc.citation.endPage | 71 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002571135 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Sorafenib | - |
dc.subject.keywordAuthor | Coronary artery vasospasm | - |
dc.subject.keywordAuthor | Variant angina | - |
dc.subject.keywordAuthor | Tyrosine kinase inhibitor | - |
dc.subject.keywordAuthor | Vascular endothelial growth factor inhibitor | - |
dc.identifier.url | https://www.e-jlc.org/journal/view.php?doi=10.17998/jlc.20.1.67 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.